A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer
Novel therapies have significantly improved survival for non-metastatic non-small cell lung cancer (NSCLC), however recurrence remains a challenge. Current treatment and surveillance strategies rely on imaging and clinical assessments with limited sensitivity in early detection of disease progression. Liquid biopsy-mediated detection of minimal residual disease (MRD) allows monitoring of tumor activity at the molecular level before clinical and radiologic progression. Here, we review the current evidence for MRD in the adaptive management and surveillance of non-metastatic NSCLC, focusing on the missing links that prevent its widespread clinical adoption.
Authors
- Andriani Charpidou (ORCID: https://orcid.org/0000-0002-5107-6430)
- Sofia Agelaki (ORCID: https://orcid.org/0000-0002-7850-0457)
- Kleita Michaelidou (ORCID: https://orcid.org/0000-0002-4425-7145)
- Simon A. Joosse (ORCID: https://orcid.org/0000-0002-4296-5615)
- Aristeidis E. Boukouris (ORCID: https://orcid.org/0000-0002-7106-0356)
- Konstantinos N. Syrigos
- Dimitriοs Mavroudis (ORCID: https://orcid.org/0000-0003-0587-1713)
Institutions
- University of Crete (GR)
- Universität Hamburg (DE)
- National and Kapodistrian University of Athens (GR)
- University Medical Center Hamburg-Eppendorf (DE)
- University Hospital of Heraklion (GR)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1038/s41698-025-00984-9
- Citations
- 16
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 24.29
Funders
- Hellenic Society of Medical Oncology